Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Tuberculosis, Pulmonary

• Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
• Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
• Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
• Phase 2 Trial Assessing TBAJ876 or Bedaquiline, With Pretomanid and Linezolid in Adults With Drug-sensitive Pulmonary Tuberculosis
• Pragmatic Optimized Rifampicin Trial
• Evaluating the Early Bactericidal Activity, Safety and Tolerability of Nebulised RESP301 in Adults With Tuberculosis
• Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
• BTZ-043 Dose Evaluation in Combination and Selection
• Study to Evaluate EBA, Safety and Tolerability of Carbapenems in Adults With Pulmonary Tuberculosis
• PanACEA - STEP2C -01
• Short-course Regimens for the Treatment of Pulmonary Tuberculosis
• The BLAST- 1 Trial - Cephalexin+Amoxicillin-clavulanate for Tuberculosis
• A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis
• Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
• A Phase 1, Drug-Drug Interaction Study to Evaluate Safety, Tolerability, and Induction Potential of TBAJ-876 on CYP3A4 and P-glycoprotein and Inhibition Potential of TBAJ-876 on P-glycoprotein in Healthy Adults
• Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
• A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Ethionamide Alone and in Combination With BVL-GSK098
• Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
• EBA, Safety and Tolerability of Sanfetrinem Cilexetil
• Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in Combination With Delamanid or Bedaquiline, Delamanid in Combination With Bedaquiline, or Standard of Care in Male and Female Participants Aged 18 to 65 Years With Pulmonary Tub
• Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB
• Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis
• Study of Interferon-Gamma in the Complex Treatment of Patients Infected With HIV and Tuberculosis
• Modified BPaL Regimen for Managing Pre-XDR TB and MDR (TI/NR) TB in India
• Linezolid Dosing Strategies in Drug-Resistant TB
• Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)
• Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
• Study to Evaluate Safety, Tolerability, and the PK Profile of TBI-223 in Healthy Subjects
• Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB
• Effect of Smoking Cessation on Tuberculosis Treatment Outcomes
• A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2
• Treating Tuberculosis With the Lipid Lowering Drug Atorvastatin in Nigeria(ATORvastatin in Pulmonary TUBerculosis)
• Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide
• Early Bactericidal Activity Safety Pulmonary Tuberculosis Pyrifazimine (TBI-166)
• Evaluation of Early Bactericidal Activity and Safety in Pulmonary Tuberculosis With WX-081
• Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis
• PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE)
• Rosuvastatin Evaluation as a Tuberculosis Treatment Adjunct
• Evaluate Safety, Tolerability, PK of TBAJ-876 in Healthy Adults
• Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)
• Novel Triple-dose Tuberculosis Retreatment Regimen
• Economic Evaluation of New MDR TB Regimens
• Efficacy and Safety of Isoniazid, Rifampicin and Moxifloxacin for the Intensive Phase of Initial Therapy of PTB
• A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant (DR-TB) Pulmonary TB Volunteers (PaSEM)
• Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis
• Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
• PRACTECAL-PKPD Sub Study
• BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
• PanACEA Sutezolid Dose-finding and Combination Evaluation
• Azacytidine During Anti-tuberculosis Therapy
• Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
• StAT-TB (Statin Adjunctive Therapy for TB): A Phase 2b Dose-finding Study of Pravastatin in Adults With Tuberculosis
• Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
• Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple Dosing
• A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults
• Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis
• A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis
• A Single Ascending Dose Study of BTZ043
• A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)
• Pilot Clinical Trial of PRS TB Regimen I - Phase II
• An Early Bactericidal Activity, Safety and Tolerability of GSK3036656 in Subjects With Drug-sensitive Pulmonary Tuberculosis
• Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis
• Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation
• Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
• RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection
• Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz
• A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371
• Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
• Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB
• Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis
• Safety and Immunogenicity Study of GX-70 in TB Patient
• Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix)
• Prevention of Tuberculosis in Prisons
• Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis
• A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK
• Using Biomarkers to Predict TB Treatment Duration
• Doxycycline in Human Pulmonary Tuberculosis
• Evaluating Newly Approved Drugs for Multidrug-resistant TB
• Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
• Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis
• A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis
• Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia
• Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis
• Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers
• NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis
• Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis
• Shortening Treatment by Advancing Novel Drugs
• A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis
• Research on New Regimens for Retreatment Pulmonary Tuberculosis
• Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis
• A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)
• Assessing PA-824 for Tuberculosis (the APT Trial)
• A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.
• Optimization of the TB Treatment Regimen Cascade
• Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis
• Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection
• Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design
• Immune Reconstitution in Tuberculosis Disease
• Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)
• Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis
• Clinical Trial of Phenylbutyrate and Vitamin D in Tuberculosis (TB)
• Intensive Smoking-cessation Intervention Versus Smoking-cessation Advice in Smear-positive Patients With Pulmonary Tuberculosis
• Evaluation of 8 Weeks of Treatment With the Combination of Moxifloxacin, PA-824 and Pyrazinamide in Patients With Drug Sensitive and Multi Drug-Resistant Pulmonary Tuberculosis (TB) (NC-002)
• Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis
• Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment
• Safety, Tolerability, Extended Early Bactericidal Activity and PK of Higher Doses Rifampicin in Adults With Pulmonary TB
• Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
• Homeopathy as an Adjuvant to Chemotherapy Improves Clinical Outcome in Relapsed Pulmonary Tuberculosis
• Early Bactericidal Activity (EBA) of SQ109 in Adult Subjects With Pulmonary TB
• Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001)
• Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (TMC207-CL001)
• Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers
• Latency in Pulmonary Tuberculosis
• Replacement of Vitamin D in Patients With Active Tuberculosis
• High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis
• Pharmacokinetic Study for Anti-tuberculosis Drugs
• Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis (CL-010)
• Comparing Daily vs Intermittent Regimen of ATT in HIV With Pulmonary Tuberculosis
• Controlled Comparison of Two Moxifloxacin Containing Treatment Shortening Regimens in Pulmonary Tuberculosis
• Prospective Study of N-acetyltransferase2 (NAT2) and Cytochrome P4502E1 (CYP2E1) Gene as Susceptible Risk Factors for Antituberculosis (ATT) Induced Hepatitis
• Study of Daily Rifapentine for Pulmonary Tuberculosis
• Micronutrient Supplementation in in Paediatric Pulmonary Tuberculosis
• Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis
• Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis
• Linezolid to Treat Extensively-Drug Resistant Tuberculosis
• TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
• A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB)
• L-arginine and Vitamin D Adjunctive Therapy in Pulmonary Tuberculosis (TB)
• Rapid Diagnosis of Pulmonary Tuberculosis
• Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)
• PA-824-CL-007: Phase IIa Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis
• Pulmonary Tuberculosis and Vitamin D
• MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis
• Metronidazole for Pulmonary Tuberculosis (South Korea)
• Trial of Adjunctive Vitamin D in Tuberculosis Treatment
• A RCT of Prednisone as Adjunctive Therapy for Hospitalized Patients With Pulmonary TB and HIV Co-infection
• Safety, Efficacy and Pharmacokinetics of OPC-67683 in Patients With Pulmonary Tuberculosis
• Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
• Pimonidazole Hydrochloride to Detect Low Oxygen in Tuberculosis-Infected Lungs
• A Clinical Trial to Study the Effect of the Addition of Vitamin D to Conventional Treatment in New Pulmonary Tuberculosis Patients
• Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)
• A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis
• Multicenter Trial for the Evaluation of a Fixed Dose Combined Tablet for the Treatment of Pulmonary Tuberculosis
• TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment
• Vitamin A Therapy for Tuberculosis
• TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis
• Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis
• Interferon Gamma for Drug Resistant Tuberculosis
• A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDR
• A Pilot Study of Methodology to Rapidly Evaluate Drugs for Bactericidal Activity, Tolerance, and Pharmacokinetics in the Treatment of Pulmonary Tuberculosis Using Isoniazid and Levofloxacin